Best of ASCO - 2014 Annual Meeting

 

Welcome

Neoadjuvant Therapy

Breast Cancer—Local/Regional/Adjuvant

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.

Soong June Bae

587

Association of pathologic non-complete response of axillary node with outcome after neoadjuvant chemotherapy in node positive breast cancer.

Shin-Cheh Chen

e12101

Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.

Nour Abuhadra

572

Biological behavior of HER2+ breast cancer: Differences based in hormone receptor expression.

Maria Joao Ribeiro Da Silva

e12120

Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) ± palbociclib (P).

Vera Martins

570

Biomarkers involved in the neoadjuvant therapy response in triple-negative and Her2+ subtypes breast cancer.

Salvador Bofill

e12098

CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

William M. Sikov

591

Circulating cell-free DNA (ctDNA) assessments before, during, and after neoadjuvant therapy (NAC) in nonmetastatic inflammatory breast cancer (IBC).

Carolyn S. Hall

e12113

Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC).

Luca Cavallone

594

Clinical utility of SERUM extracelullar domain of HER2 receptor (ECD) in HER2-positive breast cancer.

Ariadna Gasol Cudós

e12086

Clinical value of CTC in predicting the efficacy of treatment in breast cancer.

Yidong Zhou

e12104

Comparative efficacy of neoadjuvant to adjuvant chemotherapy for the treatment of early-stage HER2 negative breast cancer: A population-based analysis.

Nathalie LeVasseur

e12100

Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.

Ning Liao

579

Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.

Barbara Seliger

588

Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).

Sahil Seth

586

Development and external validation of a deep learning model for predicting response to HER2-targeted neoadjuvant therapy from pretreatment breast MRI.

Manasa Vulchi

593

Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

Jonas C. S. Bergh

501

Doxorubicin response prediction in neoadjuvant breast cancer therapy.

Anna Sofie Kappel Buhl

e12119

Efficacy and safety of intensified platinum-based neoadjuvant chemotherapy in locally advanced triple-negative breast cancer: Preliminary results of non-randomized phase II study.

Elena Glazkova

e12116

Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC.

Sahil Seth

595

Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.

Xavier Pivot

580

Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical changes which guides the optimal adjuvant therapy.

Tarek Mohamed Ahmed Abdel-Fatah

590

Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.

Sibylle Loibl

509

FDG uptake to reflect NLR and expression levels of TILs and PD-L1 in patients with primary breast cancer: Tumor inflammation and immunity.

Takaaki Fujii

e12110

Genomic profiling of residual tumor after neoadjuvant chemotherapy for breast cancer.

Masaya Hattori

e12106

Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.

Aranzazu Fernandez-Martinez

571

GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

Peter A. Fasching

506

Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

Esther Pohl-Rescigno

573

Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.

Yvonne Brandberg

583

HER2 cluster amplification as a factor of an especial sensitivity for anti-HER2 neoadjuvant therapy with biosimilar of trastuzumab in Russian women with breast cancer stage II-III.

Irina Vladimirovna Kolyadina

e12102

HER2-positive breast cancer: Combined 18F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after preoperative chemotherapy with trastuzumab.

Laura Vincent

e12095

Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases.

Wim Verhaegh

589

Impact of discordance in estrogen receptor, progesterone receptor, and Ki-67 after neoadjuvant chemotherapy in breast cancer on survival.

Yu-Qin Ding

e12079

Impact of serum vitamin D on the response and the prognosis in breast cancer patients treated with neoadjuvant chemotherapy.

Eriko Tokunaga

e12088

Investigating the utility of breast cancer (BC) molecular signatures and immune signature profiling (ISP) as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy + trastuzumab (NAC+T) in HER2+ BC.

Salomon M. Stemmer

e12109

Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initiative randomized clinical trial.

Rowan T. Chlebowski

520

Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer.

Mohammed Oukkal

e12080

Nomogram for predicting axillary lymph node pathological complete response in node-positive breast cancer patients after neoadjuvant chemotherapy.

Wenyan Wang

e12090

NOTCH3 expression in metastatic TNBC cells.

Antonino Bonaventura D'Assoro

e12123

NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).

Sandra M. Swain

511

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

Charles E. Geyer

TPS605

On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.

Stephen James Luen

574

Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.

Emre Koca

584

Outcomes of Hispanic/Latino women with triple-negative breast cancer who achieve a complete pathologic response after neoadjuvant chemotherapy.

Alexander Philipovskiy

e12081

Pathologic complete response and serial circulating tumor cell monitoring during neoadjuvant therapy in nonmetastatic triple-negative breast cancer patients.

Carolyn S. Hall

e12111

Pathologic response to neoadjuvant therapy with nabpaclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.

Juan David Cardenas

e12117

Pathological complete response rate (pCR) in thirty-three women with triple-negative breast cancer (TNBC) treated with a neoadjuvant carboplatin-based regimen.

Avani Chopra

e12099

Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].

Jisun Kim

576

Phase II study of preoperative chemotherapy versus standard postoperative chemotherapy in HR-negative HER2-positive breast cancer patients.

Meng Xiu

e12118

Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.

Maryann J. Kwa

TPS604

Predicting response to neoadjuvant chemotherapy in nonmetastatic hormone receptor-positive breast cancer using 21-gene Breast Recurrence Score test.

Romy Jose Thekkekara

e12093

Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC).

Elizabeth Anne Comen

592

Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.

Miguel J. Gil Gil

575

Quality of life after preoperative radio-/chemotherapy in locally advanced breast cancer patients.

Christiane Matuschek

e12083

Race and response to neoadjuvant chemotherapy according to MammaPrint risk.

Raquel Nunes

578

Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.

Benjamin James Hall

e12108

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).

Priyanka Sharma

516

Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer.

Maximilian Marhold

e12114

Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).

Giacomo Pelizzari

577

Sequence of anthracyclines and taxanes in the neoadjuvant chemotherapy of HER2-negative breast cancer: Experience of a Brazilian oncological center.

Daniel D’Almeida Preto

e12105

Serial circulating tumor DNA analysis indicating the efficacy and prognosis of neoadjuvant chemotherapy for locally advanced breast cancer.

Yidong Zhou

e12089

Significance of systemic and local immune responses to the pathological therapeutic effect of neoadjuvant chemotherapy in breast cancer.

Ryungsa Kim

e12084

Survival and recurrence of breast cancer patients with pathologic complete response after neoadjuvant chemotherapy.

Young Joo Lee

e12121

TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker.

Erica L. Mayer

507

The diagnostic accuracy of 12-point core biopsy of a tumor bed compared to the study of surgically obtained breast tissue in patients with locally advanced triple-negative or HER2-positive breast cancer after neoadjuvant systemic and targeted therapy.

Petr Krivorotko

e12097

The role of stromal tumor infiltrating lymphocytes (sTILs) as a predictive biomarker for carboplatin-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC).

Elaine M. Walsh

e12085

The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: A single-center experience.

Yurong Zheng

e12082

Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation.

Evthokia Hobbs

585